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Abstract 
 
Dysosmia in PD (Parkinson’s Disease) may result from changes in the 
olfactory apparatus or in structures involved in olfactory perception. 
Previous work1,2 has suggested that deep brain stimulation (DBS) pa-
tients have improved odor discrimination in stimulation-on/medication-
off state in comparison to their own scores in a stimulation-off/
medication-off state.  What remains unclear is whether it is the ON 
state itself or an effect of stimulation that leads to improved olfaction. 
In this study we evaluate dysosmia in two PD cohorts in the ON state, 
those treated with medication alone and those treated with medication 
and DBS.  
 
A prospective study geared at improving predictive value of olfactory 
testing with a battery of psychological tests enrolled 45 PD patients 
and 44 controls.  Of the PD patients, 9 had bilateral STN (subthalamic 
nucleus) DBS and 36 were medically treated. Subset analysis of PD 
patients with and without DBS placement revealed no difference in ap-
athy or depression.  DBS patients had better olfaction on UPSIT (Univ 
of Pennsylvania Smell Identification Test)  (p<0.05).  No difference 
was noted in disease severity, gender, smoking status, medication 
dosing, use of dopamine agonists, or maximal olfactory sulcus depth 
on MRI.  DBS patients were significantly younger, however inter-group 
differences in UPSIT scores exceeded those seen in our control cohort 
with similar ages.  
 
This study provides further data that DBS patients have improved ol-
faction.  It also provides preliminary evidence that DBS with medica-
tion improves dysosmia to a greater extent than medication alone.  
This may result from indirect stimulation of olfactory processing cen-
ters or changes in olfactory circuitry metabolism.   
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Introduction 
 
Deep brain stimulation (DBS) is used in the 
treatment of Parkinson’s Disease (PD), and 
has been shown to improve motor symptoms 
to a greater extent than optimal medical ther-
apy in selected patients.3  In addition to mo-
tor symptoms, PD is characterized by a set of 
autonomic, cognitive, and emotional non-
motor symptoms.  Olfaction is lost early in 
the disease process of idiopathic PD.  A 2006 
practice parameter statement regarding the 
diagnosis of PD concluded that olfaction 
testing could help to differentiate new-onset 
idiopathic PD from other Parkinsonian syn-
dromes.4,5 
 
Our study was designed to test several sur-
veys of non-motor symptoms of PD for their 
potential as diagnostics in an office-based 
setting.  The University of Pennsylvania 
Smell Identification Test (UPSIT)6 differs 
from other olfactory tests because of its abil-
ity to be self-administered and its everyday 
relevance.  It is a 40-question forced choice 
scratch-and-sniff test in which fewer than 18 
correct answers indicates anosmia.  Among 
the 45 PD patients recruited for the study, 
nine had received bilateral subthalamic nu-
cleus (STN) deep brain stimulation.  This 
analysis investigates the difference in non-
motor symptoms, particularly olfaction, be-
tween patients treated medically and those 
treated with medical therapy combined  
with DBS.   
Methods 
 
After obtaining permission from the Institu-
tional Review Board, subjects were recruited 
from the neurology, surgery, and otolaryn-
gology clinics at U Mass University Hospital 
and provided written informed consent.  All 
subjects were free of cognitive impairment 
and of ongoing respiratory infections.  Pa-
tients were determined by their treating neu-
rologist to have a diagnosis of idiopathic PD7 
of Hoehn and Yahr stage 1-3, and to be free 
of confounding psychiatric disorders.  Con-
trols were determined by their treating physi-
cian to be free of PD and psychiatric disor-
ders.  Within the patient group, 9 subjects 
had bilateral DBS placement in the STN. 
 
Subjects completed four surveys: UPSIT,6 
the Beck Depression Inventory (BDI),8 the 
Apathy Evaluation Scale – Self-administered 
version (AES),9 and the UK Parkinson’s Dis-
ease Society non-motor symptoms assess-
ment questionnaire (PDS).10  All surveys 
were self-administered in writing following 
written instructions.  A research assistant was 
available to answer questions if necessary. 
 
Olfaction re-testing was performed with 5 of 
the 9 DBS patients in a stimulator-off/
medication-on state.  During these tests, the 
DBS stimulators were off for a minimum of 
30 minutes.  Medication use was not varied. 
 
Comparisons were analyzed with chi-square,  
2 
Table 1 DBS  
(n=9) 
Medically treated 
(n=36) 
p-value 
Age 61   (55-68) 71   (53-88) 0.01 
Hoehn and Yahr Stage 2.83   (2-3) 2.44   (1-3) 0.07 
Age at Disease Onset* 46 63 0.003 
Duration of Disease* 15 8 0.002 
% Female 33 % 22 % 0.49 
Current Smokers 0 % 6 %   
Past Smokers 22 % 31 %   
 
 
 
 
 
 
 
 
 
 
 
* Disease onset information is not available for 9 study participants  
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t-test, logistic regression, and linear regres-
sion calculations performed in Microsoft Ex-
cel (Microsoft Corp, version 11) and STATA 
(StataCorp, version 10); p< 0.05 was consid-
ered statistically significant. 
 
Results 
 
All four of the tested surveys were shown to 
be significantly better in the age-matched 
control group without PD than the PD dis-
ease group.  Olfaction in particular was 
shown to be significantly poorer in the PD 
group, and to have sufficient predictive value 
to be useful as a diagnostic tool (results not 
shown). 
 
Within the PD group, 9 patients had received 
bilateral STN DBS (Table 1).  The DBS pa-
tients were younger than the medically treat-
ed group (average age 61 vs. 71), and had 
more severe disease (Hoehn and Yahr stage 
2.83 vs. 2.44).  The DBS patients also 
demonstrated an earlier age of disease onset 
and longer disease duration.   
 
The DBS group showed significantly im-
proved olfaction (mean 19.1 ± 6.7) compared  
to the medically-treated group (mean 14.5 ± 
5.5, p < 0.05) (Figure 1).  In contrast, the 
DBS group showed more general non-motor 
symptoms (mean 13.0 ± 4.2) compared to the 
medically-treated group (mean 8.9 ± 5.7, p =  
3 
 
 
Figure 1 (on left):  Olfaction in DBS and Medically-Treated PD Patients 
 
Figure 2 (on right):  PDS Score in DBS and Medically-Treated PD Patients 
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0.05) (Figure 2).  The other two surveys, of 
depression and apathy, were not significantly 
different between the two groups.  Logistic 
regression yielded olfaction odds ratio of 
1.13 (1.00-1.29, p = 0.04) and a non-motor 
odds ratio of 1.14 (0.99 – 1.32, p = 0.05). 
 
Further analysis was conducted to assess the 
impact of demographic variability on olfacto-
ry and non-motor systems testing.  Linear 
regression conducted on the results using 
both age and gender as dependent variables 
yielded an r-squared effect size of 15%.   
 
We created age and gender matched groups 
by selecting only those patients between the 
ages of 50 and 69 with Hoehn and Yahr 
scores of 2.5 or above (Table 2).  In these 
similar groups, the differences in olfaction 
and non-motor symptoms remained signifi-
cant (olfaction p < 0.05, non-motor p = 0.05). 
 
We then investigated the role of stimulation 
in olfactory processing by retesting 5 of the 9 
DBS patients in a stimulator-off/medication-
on state.  As a group, their olfaction was the 
same.   
 
Conclusions 
 
There are a number of reasons why olfaction 
may be different between the DBS/
medication and medication alone cohorts.  In  
 
part, the difference between our two groups 
may be a result of changes in metabolism 
either in the striatum, other basal ganglia are-
as, or potentially in other regions of the 
brain.  Changes in metabolism in the striatum 
and thalamus in PD is complex and involves 
alterations in receptor availability as well as 
neurotransmitter processing.11  Studies in rats 
with 6-hydroxydopamine lesioning have 
shown a number of changes in metabolism 
with prolonged high frequency stimulation 
(HFS), including normalization of COX lev-
els in the substantia nigra with HFS.12  In the 
same model, Cytochrome oxidase I mRNA 
levels in cortical regions have also shown to 
normalize following HFS.13  HFS has thus 
been implicated in altered transcription and 
signaling in both cortex and basal ganglia.  It 
is plausible that long term HFS stimulation 
could similarly affect regions associated with 
olfaction including the amygdala and olfacto-
ry nucleus.   
 
Alternatively, the improvement in olfaction 
with DBS may be due to indirect stimulation 
of olfaction processing centers.  A recent 
study using 18-fluorodeoxyglucose PET in 
PD patients with DBS has shown that nor-
malized resting cerebral metabolic rates of 
glucose increase with DBS around the elec-
trode, as well as in the center of the STN and 
the globus pallidus.14  Furthermore, a recent 
study in a rat model of PD suggests that cor-
4 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 DBS subset 
(n=8) 
Medically treated  subset 
(n=11) 
Age 62   (55-68) 63   (53-68) 
Hoehn and Yahr Stage 2.94   (2.5-3) 2.77   (2.5-3) 
% Female 38 % 27 % 
Linton Peters et al.: DBS-implanted Parkinson's Disease Patients
Neurol. Bull. 2: 1-6, 2010 
doi:10.7191/neurol_bull.2010.1016 
 
 
Our study is inherently limited by its small 
size.  The DBS group is smaller, and there 
are demographic differences in age and gen-
der.  Olfaction is known to degrade with age, 
and the DBS group is younger than the medi-
cally-treated group.18  Olfaction is also 
known to differ by gender, as women typi-
cally have increased UPSIT scores.18  We 
attempted to address this difference both 
through linear regression analysis and crea-
tion of an age and gender matched subset, 
but neither approach excludes the possibility 
of an underlying confounding factor.  In ad-
dition, our study population exhibited a 
broad range of disease duration, which could 
be linked to severity of both motor and non-
motor symptoms.    
 
In conclusion, we believe that this study pro-
vides preliminary evidence that patients with 
DBS have better olfaction than patients treat-
ed medically.  This stands in contrast to other 
non-motor symptoms that are worse in the 
DBS patients.  
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